Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: Potent CRF antagonist
Alternative Names: [D-Phe12,Nle21,38,Glu30,Lys33]-CRF (12-41)
Purity: ≥95% (HPLC)
Literature (1)

Biological Activity for Astressin

Astressin is a potent corticotropin-releasing factor (CRF) receptor antagonist (Ki values are 2, 1.5 and 1 nM at CRF1, CRF2α and CRF2β). Reduces ACTH secretion, blocks delayed gastric emptying and is neuroprotective in vivo.

Licensing Information

Sold with the permission of the SALK Institute

Technical Data for Astressin

M. Wt 3563.2
Formula C161H269N49O42

(Modifications: Phe-1 = D-Phe, X-10 = X-27 = Nle, Glu-19 = γ-Glu, Lys-22 = ε-Lys, Cyclized: Glu-19 - Lys-22, Ile-30 = C-terminal amide)

Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 170809-51-5
PubChem ID 16133798
Smiles [H]N[C@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](C)NC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Astressin

Solubility Soluble to 1 mg/ml in 10% Acetic acid / water

Product Datasheets for Astressin

Certificate of Analysis / Product Datasheet
Select another batch:

References for Astressin

References are publications that support the biological activity of the product.

Gulyas et al (1995) Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc.Natl.Acad.Sci.U.S.A. 92 10575 PMID: 7479843

Maecker et al (1997) Astressin, a novel and potent CRF antagonist, is neuroprotective in the hippocampus when administered after a seizure. Brain Res. 744 166 PMID: 9030428

Martinez et al (1999) Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats. J.Pharmacol.Exp.Ther. 290 629 PMID: 10411571

Perrin and Vale (1999) Corticotropin releasing factor receptors and their ligand family. Ann.N.Y.Acad.Sci. 885 312 PMID: 10816663

If you know of a relevant reference for Astressin, please let us know.

View Related Products by Product Action

View all Non-selective CRF Receptor Antagonists

Keywords: Astressin, Astressin supplier, Potent, CRF, receptor, antagonists, Corticotropin-Releasing, Factor, Non-Selective, Receptors, [D-Phe12,, Nle21,38,, Glu30,, Lys33]-CRF, (12-41), Non-selective, 1606, Tocris Bioscience

Citations for Astressin

Citations are publications that use Tocris products.

Currently there are no citations for Astressin. Do you know of a great paper that uses Astressin from Tocris? Please let us know.

Reviews for Astressin

There are currently no reviews for this product. Be the first to review Astressin and earn rewards!

Have you used Astressin?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.